Venn Therapeutics is an integrin therapeutics precision medicine company. We are developing a pipeline of novel, best-in-class agents that precisely target key mechanisms of fibrosis and NASH. TGF-β activation has the potential to intervene in hard-to-treat disease such as Idiopathic Pulmonary Fibrosis (IPF).

​

Our lead asset, VTX-001, is a monoclonal antibody that targets integrin αvβ6/1. This is currently in discovery stage. This program is wholly owned by Venn Therapeutics.

​

Our goal is to develop a novel and precise treatment for IPF patients.